L3VLUP
ProSign in

ASND · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ASNDJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ASND
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterASNDJNJ
Q3 20209 holders, $4.1bn30 holders, $26.2bn
Q4 202012 holders, $4.5bn32 holders, $26.6bn
Q1 202110 holders, $3.4bn31 holders, $25.3bn
Q2 202110 holders, $3.4bn37 holders, $25.6bn
Q3 202110 holders, $4.5bn40 holders, $24.1bn
Q4 202111 holders, $3.7bn33 holders, $25.2bn
Q1 202210 holders, $3.3bn35 holders, $28.2bn
Q2 20229 holders, $2.5bn33 holders, $26.9bn
Q3 202212 holders, $2.7bn36 holders, $25.4bn
Q4 202212 holders, $3.0bn35 holders, $27.6bn
Q1 20239 holders, $2.6bn42 holders, $24.5bn
Q2 20238 holders, $1.9bn38 holders, $25.0bn
Q3 20238 holders, $2.0bn37 holders, $18.9bn
Q4 202311 holders, $2.8bn31 holders, $19.0bn
Q1 202416 holders, $3.4bn32 holders, $19.7bn
Q2 202414 holders, $2.8bn35 holders, $20.4bn
Q3 202415 holders, $3.1bn28 holders, $22.3bn
Q4 202411 holders, $2.6bn37 holders, $20.4bn
Q1 202513 holders, $3.2bn32 holders, $20.5bn
Q2 202511 holders, $3.2bn31 holders, $18.4bn
Q3 202515 holders, $3.7bn32 holders, $23.7bn
Q4 202514 holders, $3.7bn29 holders, $27.8bn
Q1 202610 holders, $3.1bn34 holders, $35.6bn
Q2 202612 holders, $4.3bn33 holders, $39.1bn
ASND

Ascendis Pharma A

Holders
15
Reported value
$3.7bn
Buyers
6
Sellers
8

Breadth -2 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
32
Reported value
$23.7bn
Buyers
17
Sellers
13

Breadth +4 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 39 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ASND (7)

Artisan Partners LP, ExodusPoint Capital Management LP, Farallon Capital Management LLC, Hudson Bay Capital Management LP, Moore Capital Management LP, Polen Capital Management LLC, Voloridge Investment Management LLC

Only JNJ (24)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Freestone Grove Partners LP, GAMCO Investors Inc, Invesco Ltd, Jane Street Group LLC, Man Group PLC, Markel Group Inc, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, Two Sigma Advisers LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →